07:59 AM EDT, 05/21/2025 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Wednesday that the first patient has been dosed in its phase 1/2 trial to treat patients with methylthioadenosine phosphorylase-deleted solid tumors, with a focus on glioblastoma.

TNG456 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor, the company said.

"People with GBM currently have few treatment options and a five-year survival rate below 10%," Adam Crystal, president, research and development of Tango Therapeutics ( TNGX ), said in a statement. "A substantial number of patients have the potential to benefit from TNG456."